Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 32727
Body Mass Index, Components of Metabolic Syndrome and Hyperuricemia among Women in Postmenopausal Period

Authors: Vladyslav Povoroznyuk, Galina Dubetska, Roksolana Povoroznyuk


In recent years, the problem of hyperuricemia is getting a particular importance due to its increased incidence in the world population. The aim of this study was to determine uriс acid level in blood serum, incidence of hyperuricemia among women in postmenopausal period and their association with body mass index and some components of metabolic syndrome (triglyceride, cholesterol, systolic and diastolic pressure). We examined 412 women in postmenopausal period. They were divided in to the following groups: I group (BMI = 18,5-24,9), II group (BMI = 25,0-29,9), III group (BMI = 30,0-34,9), IV group (BMI > 35). We determined uric acid level among women during postmenopausal period depending on their body mass index. The higher level of uric acid was found in patients with the maximal body mass index (BMI > 35). In the I group it was 277,52 ± 8,40; in the II group – 286,81 ± 7,79; in the III group – 291,81 ± 7,56; in the IV group – 327,17 ± 12,17. Incidence of hyperuricemia among women in the I group was 10,2%, in the II group – 15,9%; in the III group – 21,2%, in the IV group – 34,2%. We found an interdependence between an uric acid level and BMI in the examined women (r = 0,21, p < 0,05). We determined that the highest level of triglyceride (F = 18,62, p < 0,05), cholesterol (F = 3,64, p < 0,05), atherogenic coefficient (F = 22,64, p < 0,05), systolic (F = 10,5, p < 0,05) and diastolic pressure (F = 4,30, p < 0,05) was among women with hyperuricemia. It was an interdependence between an uric acid level and triglyceride (r = 0,26, p < 0,05), atherogenic coefficient (r = 0,24, p < 0,05) among women in postmenopausal period.

Keywords: Hyperuricemia, uric acid, body mass index, metabolic syndrome, triglyceride, cholesterol, atherogenic coefficient, systolic and diastolic pressure, women.

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 373


[1] Chiou W, Wang M, Huang D, et al. The Relationship between Serum Uric Acid Level and Metabolic Syndrome: Differences by Sex and Age in Taiwanese. J Epidemiol. 2010;20(3):219-224. DOI: 10.2188/jea.JE20090078.
[2] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-1821. DOI: 10.1056/NEJMra0800885.
[3] Koga M, Saito H, Mukai M, Kasayama SY. Factors contributing to increased serum urate in postmenopausal Japanese females. Climacteric. 2009;12(2):146-152. DOI: 10.1080/13697130802607719.
[4] Kuwabara M, Kuwabara R, Niwa K et al. Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. Nutrients. 2018;10(8):1011. DOI: 10.3390/nu10081011.
[5] Liu DM, Jiang LD, Gan L, Su Y, Li F. Association between serum uric acid level and body mass index insex- and age-specific groups in southwestern china. Endocr Pract. 2019;25(5):438-445. DOI: 10.4158/EP-2018-0426.
[6] Povoroznyuk VV, Dubetska GS. Hyperuricemia and age. Gerontologija. 2012; 13(3):149-153.
[7] Terkeltaub R. Gout and other crystal arthropathies. 2012:357.
[8] Trifiro G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694-700. DOI: 10.1136/annrheumdis-2011-201254.
[9] Wallace KL.Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2008.31(8):1582-1587.
[10] Watanabe S. Uric acid, huminoid evolution and the pathogenesis of salt-sensitivity. Hypertension.2002:40:355-360.
[11] Wu LJ, Song XY. Epidemiological study on hyperuricemia and gout in Uygur population in Turpan area of Xinjiang. Beijing Da Xue Xue Bao. 2012;44(2):250-253.
[12] Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2):156-160.
[13] Yang T, Chu CH, Bai CH, et al. Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. Atherosclerosis. 2012;220(2):525-531. DOI: 10.1016/j.atherosclerosis.2011.11.014.
[14] Yue JR. Association of serum uric acid with body mass index among long-lived Chinese. Exp Gerontol. 2012;47(8):595-600.
[15] Zhang Q, Lou S, Meng Z, Ren X. Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. Clin Rheumatol. 2011;30(6):777-787. DOI: 10.1007/s10067-010-1660-7.
[16] ZhangW. EULAR evidence based recommendation for gout. Ann Rheum Dis. 2006:10;1301-1311.
[17] . Zhang Y. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 2013;375(1-2):89-96.
[18] Zhang L. Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. Am J Epidemiol. 2013;177(9):923-32.
[19] Zhang HW. A cross-sectional study on serum uric acid level and the distribution of metabolic syndrome among Uigur, Han and Kazak prediabetic groups in Xinjiang Zhonghua Liu Xing Bing Xue Za Zhi. 2013;34(10):958-960.
[20] ZhuY, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141. DOI: 10.1002/art.30520.
[21] Zoppini G. The role of serum uric acid in cardiovascular disease in Type 2 diabetic and non-diabetic subjects: A narrative review. J Endocrinol Invest. 2011;34(11):881-886.
[22] Zoccali C, Mallamaci F. Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep. 2013;15(6):531-537.DOI:10.1007/s11906-013-0391-y.
[23] Zoccali C. Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep. 2013;15(6):531-537.
[24] Ziaee A. Association between Uric Acid and Metabolic Syndrome in Qazvin Metabolic Diseases Study (QMDS), Iran. J Health Sci. 2012;5(1):155-165.